Angiogenesis and Anti-Angiogenic Molecularly Targeted Therapies in Malignant Gliomas

被引:54
作者
Argyriou, Andreas A. [1 ]
Giannopoulou, Efstathia [1 ]
Kalofonos, Haralabos P. [1 ]
机构
[1] Univ Patras, Sch Med, Univ Hosp, Div Oncol,Dept Med, GR-26504 Rion, Greece
关键词
Malignant gliomas; Angiogenesis; Angiogenic switch; Monoclonal antibodies; Tyrosine kinase inhibitors; ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB PLUS IRINOTECAN; BRAIN-TUMOR CONSORTIUM; HIGH-GRADE GLIOMAS; FACTOR RECEPTOR; PHASE-II; GLIOBLASTOMA-MULTIFORME; IN-VIVO; RECURRENT GLIOBLASTOMA; FACTOR VEGF;
D O I
10.1159/000218165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is considered to be a regulating factor of vascular development and growth for malignant gliomas, including glioblastoma multiforme (GBM) and anaplastic astrocytomas. The mechanism of angiogenesis is primarily mediated by hypoxia through chronic activation of the HIF pathway leading to the production of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor. Alternatively, it can be triggered by genetic factors. The VEGF/VEGFR-2 is the predominant angiogenic signalling pathway in malignant gliomas. Currently, anti-angiogenic molecularly targeted therapies, including administration of monoclonal antibodies or tyrosine kinase inhibitors (TKIs), are being increasingly adopted for treating GBMs. This approach is based on the ability of anti-VEGFRs monoclonal antibodies to decrease vascular permeability and perfusion, whereas the use of TKIs is mainly based on their capacity to interfere with cell communication, receptor signaling and growth of tumours. Our aim is to review current knowledge on angiogenesis as a molecular pathogenetic mechanism of malignant gliomas and to critically look at and discuss antiangiogenic molecularly targeted therapies for these brain malignancies. We also highlight areas of future research to pursue. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:1 / 11
页数:11
相关论文
共 100 条
[1]  
Argyriou AA, 2008, ANN ONCOL, V19, P58
[2]   Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies [J].
Argyriou, Andreas A. ;
Antonacopoulou, Anna ;
Iconomou, Gregoris ;
Kalofonos, Haralabos P. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 69 (03) :199-210
[3]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[4]   αvβ3 and αvβ5 integrin expression in glioma periphery [J].
Bello, L ;
Francolini, M ;
Marthyn, P ;
Zhang, JP ;
Carroll, RS ;
Nikas, DC ;
Strasser, JF ;
Villani, R ;
Cheresh, DA ;
Black, PM .
NEUROSURGERY, 2001, 49 (02) :380-389
[5]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[6]   Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors [J].
Bokstein, Felix ;
Shpigel, Shulim ;
Blumenthal, Deborah T. .
CANCER, 2008, 112 (10) :2267-2273
[7]   Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells [J].
Bouloumié, A ;
Schini-Kerth, VB ;
Busse, R .
CARDIOVASCULAR RESEARCH, 1999, 41 (03) :773-780
[8]   The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis [J].
Brat, DJ ;
Bellail, AC ;
Van Meir, EG .
NEURO-ONCOLOGY, 2005, 7 (02) :122-133
[9]  
BREM S, 1992, CANCER, V70, P2673, DOI 10.1002/1097-0142(19921201)70:11<2673::AID-CNCR2820701118>3.0.CO
[10]  
2-F